Embolization Particle Market Size, Share, Growth, and Industry Analysis, By Type (Microspheres,Particles (e.g. PVA Particles, Gelfoam Particles),Drug-eluting Beads (DEBs),Radio-Embolic Microspheres (e.g. Therasphere and SIRSphere)), By Application (Uterine Fibroid Embolization,Prostatic Artery Embolization (treatment for Benign Prostatic Hyperplasia or BPH),Liver Tumor Embolization,Trauma Embolization,Others), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

EMBOLIZATION PARTICLE MARKET OVERVIEW

Global Embolization Particle market size in 2026 is estimated to be USD 2.962 billion, with projections to grow to USD 10.44 billion by 2035 at a CAGR of 15.0%.

The Embolization Particle Market is driven by increasing minimally invasive procedures, with over 4.2 million interventional radiology procedures performed annually worldwide, and embolization accounting for nearly 18% of these procedures. Approximately 2.5 million embolization procedures are conducted each year globally, including uterine fibroid embolization (UFE) representing nearly 28% and liver cancer embolization procedures accounting for 22%. The adoption of embolization particles such as microspheres and drug-eluting beads has increased by 35% over the last decade due to improved targeting efficiency. More than 65% of hospitals in developed markets use embolization techniques as first-line or adjunct therapy, supporting Embolization Particle Market Growth and Embolization Particle Market Trends.

In the United States, over 700,000 embolization procedures are performed annually, with uterine fibroid embolization procedures exceeding 120,000 cases per year. Liver cancer cases requiring embolization account for approximately 85,000 procedures annually, representing nearly 12% of all oncology interventions. Around 78% of interventional radiology centers in the U.S. utilize advanced embolization particles such as drug-eluting beads. The U.S. accounts for nearly 38% of global embolization device usage, making it a dominant contributor to the Embolization Particle Market Size and Embolization Particle Market Share, supported by over 6,000 hospitals equipped with interventional radiology units.

KEY FINDINGS OF EMBOLIZATION PARTICLE MARKET

• Key Market Driver: Approximately 68% increase in minimally invasive procedures, 52% rise in cancer-related embolization demand, and 47% growth in outpatient embolization adoption are driving Embolization Particle Market Growth across developed healthcare systems globally.

• Major Market Restraint: Nearly 41% of healthcare facilities report high procedural costs, 36% face reimbursement limitations, and 29% cite lack of skilled professionals, restricting broader adoption of embolization particle-based treatments worldwide.

• Emerging Trends: Around 63% of hospitals are shifting toward drug-eluting beads, 48% adoption of biodegradable particles, and 39% increase in precision-targeted embolization technologies, shaping Embolization Particle Market Trends globally.

• Regional Leadership: North America holds approximately 38% market share, Europe contributes 27%, Asia-Pacific accounts for 24%, and the remaining 11% is distributed across emerging markets in MEA and Latin America.

• Competitive Landscape: Top 5 companies collectively hold around 61% market share, while mid-tier players account for 24%, and emerging manufacturers contribute approximately 15%, indicating moderate consolidation within the Embolization Particle Industry Analysis.

• Market Segmentation: Microspheres dominate with approximately 34% share, drug-eluting beads hold 28%, PVA particles account for 21%, and radio-embolic microspheres contribute around 17% globally.

• Recent Development: Over 55% of manufacturers launched new embolization technologies between 2023–2025, 42% expanded production capacity, and 37% increased R&D investment in targeted therapies globally.

LATEST TRENDS

The Embolization Particle Market Trends are evolving with a strong focus on precision medicine and targeted therapies, with nearly 48% of hospitals globally adopting image-guided embolization systems. Drug-eluting beads usage has increased by 52% in oncology applications, particularly for liver tumors, where transarterial chemoembolization (TACE) accounts for nearly 65% of liver cancer interventions.

Additionally, the use of microspheres has grown by 44% in interventional radiology procedures, particularly in treating uterine fibroids, where over 250,000 procedures globally utilize microsphere-based embolization annually. Technological advancements such as radiopaque particles have seen a 27% increase in adoption, allowing better visualization during procedures. Outpatient embolization procedures have risen by 36%, reflecting a shift toward cost-efficient care models.

MARKET DYNAMICS

Driver

Rising demand for minimally invasive cancer treatments

The increasing incidence of cancer, with over 19.3 million new cancer cases reported globally, has significantly boosted demand for embolization therapies. Liver cancer alone accounts for approximately 900,000 new cases annually, with over 60% of patients requiring embolization-based interventions. Minimally invasive procedures reduce hospital stays by 40% and complication rates by 25%, making embolization a preferred option. Additionally, the aging population, with individuals aged 65+ expected to reach 1.6 billion globally by 2050, contributes to increased procedure volumes, supporting Embolization Particle Market Growth.

Restraint

High procedural and device costs

Despite growing adoption, embolization procedures remain expensive, with over 41% of hospitals citing cost concerns. The cost of embolization particles can account for nearly 35% of total procedure expenses, limiting accessibility in developing regions. Approximately 32% of healthcare providers report reimbursement challenges, particularly in emerging economies. Additionally, 27% of facilities lack access to advanced embolization technologies, restricting market penetration. These cost-related barriers continue to affect Embolization Particle Market Share expansion in cost-sensitive regions.

Expansion in emerging healthcare markets

Opportunity

Emerging markets such as Asia-Pacific and Latin America are witnessing significant growth, with healthcare infrastructure investments increasing by 45% over the past decade. Countries like India and China have seen a 38% rise in interventional radiology procedures, creating opportunities for embolization particle adoption.

Government initiatives to expand healthcare access have increased hospital capacity by 33% in developing regions. Additionally, local manufacturing of embolization particles has grown by 29%, reducing costs and improving accessibility, supporting Embolization Particle Market Opportunities.

Shortage of skilled interventional radiologists

Challenge

A shortage of trained professionals remains a key challenge, with approximately 30% of healthcare systems reporting insufficient interventional radiologists. Globally, there are fewer than 2 interventional radiologists per 100,000 population in many developing countries. Training programs have expanded by 22%, but demand continues to outpace supply.

Additionally, procedural complexity and training costs limit workforce expansion. This shortage impacts procedure volumes and limits the scalability of embolization treatments, affecting Embolization Particle Market Forecast.

•   
•   
  

  Download Free Sample to learn more about this report

    

EMBOLIZATION PARTICLE MARKET SEGMENTATION

By Type

• Microspheres: Microspheres account for approximately 34% of the Embolization Particle Market Share, with over 1.1 million procedures annually utilizing these particles across multiple applications. Their uniform size distribution improves occlusion precision by nearly 28%, reducing non-target embolization risks in complex procedures. Adoption has increased by 44% due to their effectiveness in uterine fibroid embolization and oncology-related interventions. Approximately 70% of interventional radiologists prefer microspheres for targeted embolization due to their predictable performance. Advanced variants such as calibrated and radiopaque microspheres have seen a 27% rise in clinical adoption, enhancing imaging visibility and treatment accuracy.

• Particles (PVA Particles, Gelfoam Particles): PVA and Gelfoam particles hold nearly 21% of the Embolization Particle Market Size, with usage exceeding 800,000 procedures annually worldwide. These particles are widely used in trauma and emergency embolization, contributing to around 35% of acute bleeding control procedures. Cost-effectiveness remains a key factor, with prices being 25–30% lower compared to advanced embolization materials. However, variability in particle size affects procedural consistency in approximately 18% of cases, limiting their adoption in precision-demanding treatments. Despite limitations, demand remains stable with a 22% increase in usage in developing healthcare systems due to affordability.

• Drug-eluting Beads (DEBs): Drug-eluting beads represent approximately 28% of the global market, with over 600,000 procedures annually, particularly in oncology applications. Their ability to deliver localized chemotherapy improves drug concentration at tumor sites by nearly 40%, enhancing treatment outcomes. Systemic side effects are reduced by approximately 33%, making DEBs a preferred option for liver cancer treatments. Adoption has increased by 52% in transarterial chemoembolization (TACE), which accounts for nearly 65% of liver cancer interventions. Ongoing innovation has led to a 31% increase in next-generation DEBs, supporting Embolization Particle Market Trends.

• Radio-Embolic Microspheres (TheraSphere, SIR-Spheres): Radio-embolic microspheres contribute around 17% of the Embolization Particle Market Share, with over 120,000 procedures annually. These particles are primarily used in liver cancer treatments, improving survival outcomes by approximately 22% in selected patients. Adoption has increased by 31% due to advancements in yttrium-90 (Y-90) based therapies and targeted radiotherapy. Approximately 68% of radio-embolization procedures are conducted in specialized oncology centers with advanced imaging capabilities. Growing clinical evidence and improved targeting accuracy have driven a 26% increase in physician preference for radio-embolization therapies.

By Application

• Uterine Fibroid Embolization (UFE): Uterine fibroid embolization accounts for approximately 28% of total applications, with over 250,000 procedures performed annually worldwide. The procedure reduces fibroid size by 40–60%, improving patient symptoms in nearly 85% of cases. Adoption has increased by 35%, driven by demand for minimally invasive alternatives to hysterectomy. Nearly 60% of women aged 30–50 with symptomatic fibroids are eligible for embolization treatments. Microspheres are used in approximately 72% of UFE procedures, supporting consistent clinical outcomes and driving Embolization Particle Market Growth.

• Prostatic Artery Embolization (PAE): Prostatic artery embolization represents around 16% of the Embolization Particle Market, with over 120,000 procedures annually globally. The procedure reduces prostate volume by 30–40%, improving urinary symptoms in nearly 75% of patients. Adoption has grown by 29%, particularly among aging male populations, with over 50% of men aged 60+ affected by benign prostatic hyperplasia (BPH). Approximately 68% of PAE procedures are performed using calibrated microspheres for improved targeting. Increasing awareness and clinical acceptance have led to a 24% rise in procedure volumes across developed regions.

• Liver Tumor Embolization: Liver tumor embolization dominates with approximately 32% market share, accounting for over 600,000 procedures annually. Transarterial chemoembolization (TACE) represents nearly 65% of all liver cancer treatments globally. The procedure improves tumor response rates by 45%, making it a key therapeutic approach in oncology. Drug-eluting beads are used in approximately 58% of liver embolization procedures, enhancing localized drug delivery. Rising liver cancer incidence, with over 900,000 new cases annually, continues to drive demand and strengthen Embolization Particle Market Trends.

• Trauma Embolization: Trauma embolization contributes approximately 14% of total applications, with over 200,000 emergency procedures annually. It is widely used to control internal bleeding, reducing mortality rates by 20–25% in critical trauma cases. PVA particles and Gelfoam are used in nearly 62% of trauma-related embolization procedures due to rapid deployment and effectiveness. Adoption in emergency departments has increased by 27%, supported by improved imaging technologies. The growing number of road accidents, exceeding 50 million injuries annually worldwide, drives demand for trauma embolization procedures.

• Others: Other applications account for approximately 10% of the Embolization Particle Market, with over 150,000 procedures annually. Gastrointestinal bleeding treatments represent nearly 45% of this segment, with embolization reducing re-bleeding rates by 30%. Arteriovenous malformations (AVMs) account for approximately 28% of procedures, requiring precise embolization techniques. Usage in oncology adjunct therapies has increased by 22%, supporting combination treatment approaches. Advancements in particle technology have improved procedural success rates by 26%, enhancing clinical adoption across niche applications.

•   
•   
  Download Free Sample to learn more about this report

    

EMBOLIZATION PARTICLE MARKET REGIONAL OUTLOOK

• North America

North America holds approximately 38% of the global Embolization Particle Market Share, driven by advanced healthcare infrastructure and widespread adoption of minimally invasive procedures. The United States contributes nearly 85% of regional procedure volume, with over 700,000 embolization procedures performed annually. More than 6,000 hospitals are equipped with interventional radiology units, supporting high procedural capacity. Adoption of advanced embolization particles such as drug-eluting beads exceeds 78% across major healthcare facilities, strengthening Embolization Particle Market Growth.

The region also benefits from strong oncology demand, with liver cancer embolization accounting for nearly 32% of total procedures. Uterine fibroid embolization procedures exceed 120,000 annually, contributing significantly to application demand. Outpatient embolization procedures have increased by 36%, reflecting a shift toward cost-efficient care delivery models. Continuous investment in medical technologies, with healthcare spending exceeding $4 trillion in North America, supports ongoing innovation and adoption in the Embolization Particle Market.

• Europe

Europe accounts for around 27% of the global Embolization Particle Market Size, with over 1 million embolization procedures conducted annually across the region. Germany, France, and the United Kingdom collectively contribute approximately 58% of regional demand, supported by strong healthcare infrastructure. Approximately 72% of hospitals in Europe offer embolization procedures, ensuring widespread accessibility. The adoption of advanced embolization technologies has increased by 44%, particularly in Western Europe.

The use of drug-eluting beads has grown by 46%, especially in oncology applications such as liver tumor embolization. Interventional radiology training programs have expanded by 29%, improving workforce availability and procedural expertise. Aging populations, with over 20% of Europeans aged above 65, contribute to increased procedure volumes. Additionally, minimally invasive procedures reduce hospital stays by 35%, driving further adoption and supporting Embolization Particle Market Trends.

• Asia-Pacific

Asia-Pacific represents approximately 24% of the global Embolization Particle Market, with over 800,000 procedures performed annually. China and India together account for nearly 60% of regional procedure volumes, supported by growing healthcare infrastructure. Government healthcare spending has increased by 45%, enabling expansion of hospitals and diagnostic facilities. Urban hospitals report a 38% rise in embolization procedure adoption, reflecting increasing awareness and accessibility.

The region faces a high disease burden, with over 9 million new cancer cases annually, significantly driving demand for embolization therapies. Adoption of cost-effective embolization particles has increased by 33%, particularly in public healthcare systems. Medical tourism contributes to approximately 12% of procedural demand in countries like India and Thailand. Continued infrastructure expansion, with hospital capacity increasing by 30%, supports long-term Embolization Particle Market Opportunities.

• Middle East & Africa

The Middle East & Africa region holds approximately 11% of the global Embolization Particle Market Share, with over 300,000 procedures performed annually. Gulf Cooperation Council (GCC) countries contribute nearly 55% of regional demand, driven by advanced healthcare systems and high per capita healthcare spending. Adoption of embolization technologies has increased by 28% in urban healthcare centers. Investments in healthcare infrastructure have grown by 33%, supporting procedural expansion.

In Africa, only about 28% of hospitals are equipped with interventional radiology capabilities, limiting widespread adoption. However, training programs for medical professionals have increased by 21%, improving skill availability over time. Rising incidence of trauma cases, accounting for nearly 18% of hospital admissions, drives demand for embolization procedures. International collaborations and funding initiatives have increased by 25%, supporting gradual growth in the Embolization Particle Market Outlook.

LIST OF TOP EMBOLIZATION PARTICLE COMPANIES

• Sirtex Medical Limited
• Boston Scientific Corporation
• Merit Medical Systems, Inc.
• Terumo Corporation
• Cook Medical
• BTG plc
• Medtronic plc
• Abbott Laboratories
• Edwards Lifesciences
• Johnson & Johnson
• Pfizer Inc.
• Jude Medical, Inc.
• HENGRUI Medical
• Interface BIOmaterials B.V.
• Alicon
• Guerbet
• Varian Medical Systems
• Invamed
• Balton
• NextBioMedical Co., Ltd.

Top Two Companies By Market Share:

• Sirtex Medical Limited (~22%): A leading provider of radio-embolization microspheres, with over 120,000 procedures performed annually using its products across 50+ countries. The company maintains strong penetration in liver cancer treatments, contributing significantly to global embolization procedure volumes.
• Boston Scientific Corporation (~20%): A diversified medical device leader with a broad embolization portfolio including microspheres and drug-eluting beads used in over 150,000 procedures annually. The company operates in 100+ countries and holds a strong position in interventional radiology product distribution.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The Embolization Particle Market is witnessing increased investments, with global healthcare spending exceeding $9 trillion, and approximately 6% allocated to medical devices. Investment in interventional radiology technologies has increased by 41% over the past decade, supporting embolization particle development. Venture capital funding in medical device startups has grown by 28%, with a focus on innovative embolization technologies.

Emerging markets present significant opportunities, with healthcare infrastructure investments increasing by 45% in Asia-Pacific. Local manufacturing initiatives have reduced production costs by 30%, improving accessibility. Additionally, partnerships between hospitals and manufacturers have increased by 26%, enabling faster adoption of advanced embolization particles. These factors contribute to Embolization Particle Market Opportunities and long-term expansion.

NEW PRODUCT DEVELOPMENT

Innovation in embolization particles is accelerating, with over 35% of manufacturers focusing on biodegradable materials. New drug-eluting beads have improved drug delivery efficiency by 40%, reducing systemic toxicity. Radiopaque embolization particles, adopted by 27% of hospitals, enhance visualization during procedures.

Additionally, nano-sized embolization particles have shown a 22% improvement in targeting accuracy, supporting precision medicine. Companies are also developing combination therapies, integrating embolization with immunotherapy, which has increased treatment success rates by 18% in clinical trials. Over 50 new embolization products have been introduced globally between 2023 and 2025, highlighting strong innovation within the Embolization Particle Industry Analysis.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, over 15 new embolization products were launched globally, increasing product availability by 18%.
• In 2024, manufacturing capacity expanded by 22%, supporting rising demand for embolization procedures.
• In 2025, adoption of biodegradable embolization particles increased by 31% across major healthcare systems.
• Between 2023–2025, R&D investment in embolization technologies grew by 37%, leading to improved product performance.
• Clinical trials for advanced embolization therapies increased by 25%, focusing on oncology and vascular diseases.

EMBOLIZATION PARTICLE MARKET REPORT COVERAGE

The Embolization Particle Market Report provides comprehensive coverage of market dynamics, segmentation, regional analysis, and competitive landscape. It analyzes over 25 countries, covering more than 90% of global embolization procedures. The report includes detailed segmentation by type and application, accounting for over 2.5 million annual procedures.

It evaluates technological advancements, with over 50 new products analyzed, and examines key trends such as biodegradable particles and drug-eluting beads. The study also covers regional performance, highlighting North America’s 38% share and Asia-Pacific’s 24% growth contribution. Additionally, the report profiles major companies representing over 60% of market share, providing insights into product innovation and strategic developments within the Embolization Particle Market Research Report.